计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| T608924-5mg |
5mg |
期货 ![]() |
| |
| T608924-25mg |
25mg |
期货 ![]() |
|
| 别名 | 5-[4-[3-[6-叔丁基磺酰基-4-[(4,5-二甲基-1H-吡唑-3-基)氨基]喹唑啉-7-基]氧丙基]哌嗪-1-基]-N-[(3S,5S)-5-[(2,6-二氟苯基)氨基甲酰基]-1-[(2S)-3,3-二甲基-2-[[(2S)-2-(甲基氨基)丙酰基]氨基]丁酰基]吡咯烷-3-基]吡嗪-2-甲酰胺 |
|---|---|
| 英文别名 | compound 20 |
| 规格或纯度 | Moligand™ |
| 英文名称 | 5-[4-[3-[6-tert-butylsulfonyl-4-[(4,5-dimethyl-1H-pyrazol-3-yl)amino]quinazolin-7-yl]oxypropyl]piperazin-1-yl]-N-[(3S,5S)-5-[(2,6-difluorophenyl)carbamoyl]-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-3-yl]pyrazine-2-ca |
| 作用机制 | 含 2;X-连锁凋亡抑制因子的杆状病毒 IAP 重复序列 |
| INCHI | 1S/C50H66F2N14O7S/c1-28-29(2)62-63-43(28)61-44-32-22-39(74(71,72)50(7,8)9)38(23-35(32)56-27-57-44)73-20-12-15-64-16-18-65(19-17-64)40-25-54-36(24-55-40)46(68)58-31-21-37(47(69)59-41-33(51)13-11-14-34(41)52)66(26-31)48(70)42(49(4,5)6)60-45(67)30(3)53-10/h11,13-14,22-25,27,30-31,37,42,53H,12,15-21,26H2,1-10H3,(H,58,68)(H,59,69)(H,60,67)(H2,56,57,61,62,63)/t30-,31-,37-,42+/m0/s1 |
|---|---|
| InChi Key | CHNBEZLJAQUZEX-LFRONEFISA-N |
| Smiles | CN[C@@H](C)C(=O)N[C@H](C(=O)N1C[C@H](C[C@H]1C(=O)Nc1c(F)cccc1F)NC(=O)c1cnc(cn1)N1CCN(CCCOc2cc3ncnc(Nc4n[nH]c(C)c4C)c3cc2S(=O)(=O)C(C)(C)C)CC1)C(C)(C)C |
| PubChem CID | 134496515 |
| 1. Miah AH, Smith IED, Rackham M, Mares A, Thawani AR, Nagilla R, Haile PA, Votta BJ, Gordon LJ, Watt G et al.. (2021) Optimization of a Series of RIPK2 PROTACs.. J Med Chem, 64 (17): (12978-13003). [PMID:34432979] |